Hahn Hartmut, Kammerer Bernd, DiMauro Andre, Salt Alec N, Plontke Stefan K
Department of Otorhinolaryngology Head and Neck Surgery, Tübingen Hearing Research Center, University of Tübingen, Elfriede Aulhorn-Str. 5, D-72076 Tübingen, Germany.
Hear Res. 2006 Feb;212(1-2):236-44. doi: 10.1016/j.heares.2005.12.001. Epub 2006 Jan 25.
Before new drugs for the treatment of inner ear disorders can be studied in controlled clinical trials, it is important that their pharmacokinetics be established in inner ear fluids. Microdialysis allows drug levels to be measured in perilymph without the volume disturbances and potential cerebrospinal fluid contamination associated with fluid sampling. The aims of this study were to show: (i) that despite low recovery rates from miniature dialysis probes, significant amounts of drug are removed from small fluid compartments, (ii) that dialysis sampling artifacts can be accounted for using computer simulations and (iii) that microdialysis allows quantification of the entry rates through the round window membrane (RWM) into scala tympani (ST). Initial experiments used microdialysis probes in small compartments in vitro containing sodium fluorescein. Stable concentrations were observed in large compartments (1000 microl) but significant concentration declines were observed in smaller compartments (100, 10 and 5.6 microl) comparable to the size of the inner ear. Computer simulations of these experiments closely approximated the experimental data. In in vivo experiments, sodium fluorescein 10 mg/ml and dexamethasone-dihydrogen-phosphate disodium salt 8 mg/ml were simultaneously applied to the RWM of guinea pigs. Perilymph concentration in the basal turn of ST was monitored using microdialysis. The fluorescein concentration reached after 200 min application (585+/-527 microg/ml) was approximately twice that of dexamethasone phosphate (291+/-369 microg/ml). Substantial variation in concentrations was found between animals by approximately a factor of 34 for fluorescein and at least 41 for dexamethasone phosphate. This is, to a large extent, thought to be the result of the RWM permeability varying in different animals. It was not caused by substance analysis variations, because two different analytic methods were used and the concentration ratio between the two substances remained nearly constant across the experiments and because differences were apparent for the repeated samples obtained in each animal. Interpretation of the results using computer simulations allowed RWM permeability to be quantified. It also demonstrated, however, that cochlear clearance values could not be reliably obtained with microdialysis because of the significant contribution of dialysis to clearance. The observed interanimal variation, e.g., in RWM permeability, is likely to be clinically relevant to the local application of drugs in patients.
在用于治疗内耳疾病的新药能够进行对照临床试验研究之前,确定其在内耳液中的药代动力学非常重要。微透析技术能够测量外淋巴液中的药物水平,而不会出现与液体采样相关的容量干扰和潜在的脑脊液污染问题。本研究的目的是证明:(i)尽管微型透析探头的回收率较低,但仍能从小的液体腔室中去除大量药物;(ii)透析采样伪像可以通过计算机模拟来解释;(iii)微透析技术能够定量药物通过圆窗膜(RWM)进入鼓阶(ST)的速率。最初的实验在体外含有荧光素钠的小腔室中使用微透析探头。在大腔室(1000微升)中观察到稳定的浓度,但在与内耳大小相当的较小腔室(100、10和5.6微升)中观察到显著的浓度下降。这些实验的计算机模拟结果与实验数据非常接近。在体内实验中,将10毫克/毫升的荧光素钠和8毫克/毫升的地塞米松磷酸二氢二钠盐同时应用于豚鼠的圆窗膜。使用微透析技术监测鼓阶基底转的外淋巴液浓度。应用200分钟后达到的荧光素浓度(585±527微克/毫升)约为地塞米松磷酸酯(291±369微克/毫升)的两倍。不同动物之间的浓度存在很大差异,荧光素约为34倍,地塞米松磷酸酯至少为41倍。在很大程度上,这被认为是不同动物圆窗膜通透性不同的结果。这不是由物质分析差异引起的,因为使用了两种不同的分析方法,并且两种物质之间的浓度比在整个实验中几乎保持不变,而且在每只动物获得的重复样本中差异也很明显。使用计算机模拟对结果进行解释能够定量圆窗膜的通透性。然而,这也表明,由于透析对清除率有显著贡献,微透析技术无法可靠地获得耳蜗清除率值。观察到的动物间差异,例如圆窗膜通透性的差异,可能与临床上对患者局部应用药物有关。